| Symbol | BCDA |
|---|---|
| Name | BIOCARDIA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 320 SOQUEL WAY, SUNNYVALE, California, 94085, United States |
| Telephone | +1 650 226-0120 |
| Fax | — |
| — | |
| Website | https://www.biocardia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack. Additional info from NASDAQ: |
(85% Positive) BIOCARDIA, INC. (BCDA) Announces Clinical Development Update
Read moreDirector Altman Peter 🟢 acquired 1.0K shares of BioCardia, Inc. (BCDA) at $1.23 Transaction Date: Apr 20, 2026 | Filing ID: 013052
Read more(85% Positive) BIOCARDIA, INC. (BCDA) Provides Update on timeline for ISCHEMIC HEART FAILURE SUNNYVALE
Read moreBioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreBioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
Read more(80% Positive) BIOCARDIA, INC. (BCDA) Provides Update on seen for ISCHEMIC HEART FAILURE SUNNYVALE
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05925608 | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchy… | Phase1 | Heart Failure, Systolic | Active_Not_Recruiting | 2023-08-23 | 2027-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system | DEVICE | Approved | Ischemic Heart Failure | RECRUITING | NCT06258447 |
| intravenous delivery of allogeneic bone marrow-derived MSCs | BIOLOGICAL | Phase PHASE1 | ARDS, Human | WITHDRAWN | NCT05491681 |
| Sham Treatment | OTHER | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| CardiAMP Cell Therapy System | DEVICE | Approved | Refractory Angina | ACTIVE_NOT_RECRUITING | NCT03455725 |
| Sham | OTHER | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Autologous cell therapy | BIOLOGICAL | Phase PHASE3 | Heart Failure, Systolic | COMPLETED | NCT02438306 |
| Transendocaridal Transplantation of Autologous Bone Marrow | PROCEDURE | Phase PHASE1 | Ventricular Dysfunction | COMPLETED | NCT00507468 |